Fig. 2.

IL7 decreases tumor growth in murine HNSCC models. A Schematic of experimental design for the orthotopic mEER HPV+ murine model in C57BL/6 mice. Initiation of treatment started on day 5 with two fractions of 4 Gy RT combined with 2 weeks of IL7 i.p. injections. B Tumor growth curves with untreated (n = 15), RT (n = 8), IL7 (n = 9), and RT + IL7 (n = 9) cohorts with timing of treatment indicated by yellow and black arrows. Experiments were repeated and pooled. C Kaplan–Meier survival plot for the mEER model stratified by treatment. D Individual growth curves for each treatment are shown. E Experimental design for the orthotopic LY2 HPV− murine model in BALB/c mice. Initiation of treatment starting at day 12 after implantation. One dose of 10 Gy RT was given with 2 weeks of i.p. IL7 injections. F Tumor growth curves for untreated (n = 10), IL7 (n = 7), RT (n = 8), and RT + IL7 (n = 8) groups with timing of treatments indicated by yellow and black arrows. Experiment was repeated and pooled. G Kaplan–Meier survival plot for the LY2 model stratified by treatment. H Growth of individual LY2 tumors shown for each group. Statistics were determined using one-way ANOVA testing (B, F) and log-rank testing (C, G). The mean ± SEM is shown (B, F). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001